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Background: Angiotensin-converting enzyme inhibitors have
shown antiproteinuric effects in normotensive and hypertensive
diabetic patients. Angiotensin-receptor antagonists reduce urinary
albumin excretion and the risk for renal and cardiovascular com-
plications in hypertensive patients with type 2 diabetes mellitus.
The effect of angiotensin-receptor antagonists in normotensive
diabetic patients with microalbuminuria has not yet been reported.
Objective: To assess the antiproteinuric effects of losartan in
normotensive patients with type 2 diabetes and microalbuminuria.
Design: Multicenter randomized, double-blind, placebo-con-
trolled clinical trial.
Setting: 19 outpatient clinics in the Netherlands.
Patients: 147 normotensive patients with type 2 diabetes melli-
tus and microalbuminuria.
Intervention: 74 patients were randomly assigned to receive
losartan and 73 patients were assigned to receive placebo for 10
weeks; 71 patients in each group completed the study. The losar-
tan dose was 50 mg during the first 5 weeks and 100 mg during
the subsequent 5 weeks.
Measurements: Change in urinary albumin excretion rate after 5
and 10 weeks, change in creatinine clearance and blood pressure,
and safety and tolerability of losartan.
Results: A significant 25% relative reduction in the albumin
excretion rate occurred after 5 weeks of the 50-mg losartan dose,
with further improvement over the subsequent 5 weeks with the
100-mg dose (relative reduction, 34%). In the losartan group,
creatinine clearance did not improve and blood pressure decreased
slightly. Side effects did not differ between treatment groups.
Conclusions: The angiotensin-receptor antagonist losartan re-
duces urinary albumin excretion in normotensive patients with
type 2 diabetes and microalbuminuria. In multivariate analysis, the
antiproteinuric effect of losartan was independent of the associ-
ated reduction in blood pressure. Losartan was safe and well
tolerated in these normotensive patients.
Ann Intern Med. 2003;139:90-96. www.annals.org
For author affiliations, see end of text.
Diabetes mellitus is an important cause of nephropathy,end-stage renal disease, and cardiovascular events. Ne-
phropathy occurs in about 40% of patients with type 2
diabetes, and 25% to 40% of diabetic patients in Europe
and the United States develop end-stage renal disease. In-
creased urinary albumin excretion, the first marker of kid-
ney damage, carries an increased risk for renal as well as
cardiovascular disease (1–5). Because reduction in mi-
croalbuminuria is associated with marked renal protection,
the delay or retardation of the disease process is important
in the management of diabetes mellitus (1).
Angiotensin-converting enzyme (ACE) inhibitors re-
duce albumin excretion in both normotensive and hyper-
tensive patients with type 1 or type 2 diabetes. The anti-
proteinuric effects appear to be at least partly independent
of the reduction in blood pressure caused by these agents
(6–11), although some studies have not confirmed this
finding (12). Angiotensin II is thought to play a prominent
role in the pathogenesis of diabetic nephropathy. There-
fore, both preventing the formation of angiotensin II by
ACE inhibition and blockade of the angiotensin receptor
might be renoprotective.
The trials of angiotensin-receptor antagonists in hy-
pertensive patients with type 1 or 2 diabetes mellitus and
microalbuminuria showed a reduction in albumin excre-
tion, regardless of pretreatment levels (13–20). Recently,
the angiotensin-receptor antagonist irbesartan retarded pro-
gression from microalbuminuria to overt proteinuria in hy-
pertensive patients with type 2 diabetes (21). In RENAAL
(The Reduction of Endpoints in NIDDM [non–insulin-
dependent diabetes mellitus] with the Angiotensin II An-
tagonist Losartan study) and IDNT (Irbesartan Diabetic
Nephropathy Trial), losartan and irbesartan, respectively,
reduced proteinuria and slowed the progression of diabetic
nephropathy in hypertensive patients with type 2 diabetes
(22–24).
Therefore, therapy that interferes with the renin–
angiotensin–aldosterone system should probably be initi-
ated when microalbuminuria develops in order to reduce
albumin excretion and the associated risk for overt nephrop-
athy. All previous studies on this subject investigated hyper-
tensive patients. Therefore, we conducted a multicenter
randomized, double-blind, placebo-controlled, clinical trial
with forced dose titration to investigate the effects of losartan
on urinary albumin excretion rate in normotensive patients
with type 2 diabetes and microalbuminuria. Secondary ob-
jectives were to determine the time course of the antiprotein-
uric effect, the optimal dose of losartan, effects on creatinine
clearance and blood pressure, and the safety and tolerability
of losartan in normotensive patients.
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METHODS
Study Design
In 19 outpatient clinics in the Netherlands, we con-
ducted a 20-week randomized, placebo-controlled trial.
The trial consisted of a 5-week screening and washout pe-
riod, a 10-week double-blind treatment period, and a
5-week placebo washout period. The study was performed
according to the guidelines of good clinical practice and
was approved by the institutional review board at each
center. All patients gave written informed consent.
Patients
From March 1999 through August 2001, all outpa-
tients with type 2 diabetes mellitus, microalbuminuria, and
a sitting blood pressure of 150/90 mm Hg or less were
invited to participate. Type 2 diabetes mellitus was defined
as diabetes diagnosed at age older than 30 years or con-
trolled by diet or blood glucose–lowering agents for at least
6 months. Microalbuminuria was defined as a urinary al-
bumin excretion rate of 20 to 200 g/min.
The current definition of normotension is a blood
pressure less than 140/90 mm Hg, with a blood pressure–
lowering target of less than 130/80 mm Hg in hypertensive
adults with diabetes mellitus (25, 26); however, we devel-
oped the protocol for this study in 1998, when normoten-
sion was defined as a sitting blood pressure of 160/90 mm
Hg or less. Because of this and the fact that the mean
baseline blood pressures appeared to be 135.9/78.8 mm
Hg for the losartan group and 138.3/80.3 mm Hg for the
placebo group, our study sample can be considered normo-
tensive.
We excluded patients with a myocardial infarction in
the preceding 6 months, cerebrovascular events within the
past year, unstable angina pectoris, or symptomatic heart
failure; patients with electrocardiographic abnormalities
(atrioventricular conduction disturbances, sick sinus syn-
drome, atrial fibrillation, or other clinically significant
rhythm disturbances), acute renal failure, chronic glomer-
ulonephritis, polycystic kidney disease, or a serum creati-
nine level greater than 150 mol/L (1.7 mg/dL); and pa-
tients with a glycosylated hemoglobin level greater than
10% or other relevant laboratory abnormalities. Concom-
itant use of antihypertensive agents, ophthalmic prepara-
tions containing -blocking agents, steroids, or lithium
was not allowed.
Eligible patients were included in the screening and
washout period (weeks 5 to 0). In patients not taking
blood pressure–lowering or renoprotective medication, mi-
croalbuminuria was assessed by two sequential 24-hour
urine collections before the randomization visit (week 0).
Patients could be randomly assigned if the average of these
two measurements confirmed microalbuminuria as defined
above. Eligible patients who were receiving ACE inhibi-
tors, angiotensin-receptor antagonists, or other antihyper-
tensive agents first entered a 5-week washout period. In
these patients, microalbuminuria was assessed after this pe-
riod. If therapy with such medication had been initiated to
normalize known hypertension, the patient was excluded.
Interventions
Patients who met all study criteria were randomly as-
signed in a double-blind fashion to receive losartan, 50 mg
once daily, or matching placebo (week 0). After 5 weeks of
treatment, patients initially assigned to receive 50 mg of
losartan had fixed-dose titration to 100 mg of losartan; pa-
tients initially assigned to receive placebo continued to receive
placebo. Treatment was continued at this dose for another
5 weeks, after which all patients were switched to single-
blind placebo for the last 5 weeks. At the end of this wash-
out period, patients returned for their final visit (week 15).
The study sponsor, Merck, Sharpe & Dohme, pro-
vided each center with the study medication and randomly
assigned the patients in blocks of four. The investigators
dispensed the study medication and provided the patient
with the first available allocation number. In each center,
the allocation numbers were assigned in consecutive order.
The patients had an equal probability of assignment to
either group. The randomization list was inaccessible to all
investigators. No randomization code was broken, so all
investigators and participants remained blinded to treat-
ment assignment during the entire study.
Throughout the study, patients received the standard
of care for diabetes. They were instructed not to change
their physical exercise patterns significantly because doing
so may influence proteinuria.
Outcomes
The primary end point was the change in urinary al-
bumin excretion rate from baseline to week 10. Secondary
end points were change in albumin excretion rate at week
5, change in creatinine clearance from baseline to week 10,
Context
Angiotensin-receptor antagonists reduce renal and cardio-
vascular complications in patients with type 2 diabetes and
hypertension. The effect of these drugs on normotensive
patients with type 2 diabetes is not known.
Contribution
This 10-week randomized, placebo-controlled trial showed
that in normotensive diabetic patients receiving losartan,
albumin excretion rate was significantly reduced and blood
pressure slightly decreased.
Cautions
The study included patients with systolic blood pressure up
to 150 mm Hg and was too brief to evaluate progression
of clinical renal disease. Angiotensin-receptor antagonists
hold promise in preserving renal function in patients with
type 2 diabetes without marked hypertension, but they
warrant further study.
–The Editors
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and change in systolic and diastolic blood pressures at
weeks 5 and 10. Tertiary end points were safety and toler-
ability of losartan.
Measurements
At each visit, the same investigator measured blood
pressure and pulse. Blood pressure was measured by a
sphygmomanometer, with the patient seated for 5 minutes
before the first measurement. Three replicate measure-
ments, obtained 1 minute apart, were averaged.
In each center, microalbuminuria was measured just
before every visit in two sequential 24-hour urine collec-
tions by using an immunonephelometric assay on an auto-
mated analyzer (Beckman Coulter, Brea, California). The
measurements of the two samples were averaged. Complete
laboratory evaluations (biochemistry, hematology) were
conducted at weeks 0 and 10; at weeks 5 and 15, only renal
function and electrolytes were checked. A virtual central
laboratory recalculated all laboratory results, including mi-
croalbuminuria, and corrected them for possible bias.
At weeks 0, 5, 10, and 15, adverse events were re-
corded, and medication use and adherence were checked
by counting pills. Patients were considered adherent if at
least 75% of the study drug had been taken.
Statistical Analysis
Primary and secondary end points were analyzed in
the full-analysis study sample, which consisted of all pa-
tients randomly assigned (intention-to-treat analysis). The
statistical method used was the generalized linear mixed
model for longitudinal data, which compares the differ-
ences in trends over time between both treatment groups
(27). Baseline values were used as covariates in this model,
and outcomes were adjusted by using treatment, visit, cen-
ter, and the corresponding interaction terms as fixed ef-
fects.
A generalized linear mixed model was also applied to
evaluate whether the observed changes in albumin excre-
tion rate were consistent across different baseline blood
pressures. Furthermore, an additional analysis using analy-
sis of variance was performed to evaluate whether changes
in blood pressure affected the observed changes in albumin
excretion rate.
Safety data were analyzed for all patients who took at
least one dose of study medication and for whom at least
one safety assessment was available. Statistical analysis of
these data was not done.
The study had 92% power with an  level of 0.05 to
detect a 30% difference in the change in albumin excretion
rate between the treatment groups. We used SAS software,
version 6.12 (SAS Institute, Inc., Cary, North Carolina),
for all statistical analyses.
Role of the Funding Source
The funding source had no role in the collection, anal-
ysis, or interpretation of the data or the decision to submit
the manuscript for publication.
RESULTS
Patients
Of the 236 patients enrolled in the screening period,
49 used an ACE inhibitor or angiotensin-receptor antago-
nist before enrollment and underwent initial washout. Of
Table 1. Baseline Characteristics of the Full-Analysis Study Sample*
Characteristic Losartan Group (n  74) Placebo Group (n  73)
Age, y 56.9  11.0 58.5  12.3
Men, n (%) 50 (68) 51 (70)
Race or ethnicity, n (%)
White 59 (80) 63 (86)
Black 5 (7) 3 (4)
Asian 2 (3) 0 (0)
Other 8 (11) 7 (10)
Body mass index, kg/m2 32.0  16.2 28.7  4.5
Blood pressure, mm Hg
Systolic 135.9  10.4 138.3  9.7
Diastolic 78.8  9.4 80.3  7.5
Pulse, beats/min 79.2  11.5 76.4  11.3
Biochemistry
Serum creatinine level, mol/L (mg/dL) 87.6  20.8 (1.0  0.2) 87.7  17.5 (1.0  0.2)
Total cholesterol level, mmol/L (mg/dL) 5.3  1.0 (204.6  38.6) 5.4  0.9 (208.4  34.7)
HDL cholesterol level, mmol/L (mg/dL) 1.2  0.3 (46.3  11.6) 1.2  0.5 (46.3  19.3)
LDL cholesterol level, mmol/L (mg/dL) 3.1  0.9 (119.7  34.7) 3.2  0.8 (123.5  30.9)
Triglyceride level, mmol/L (mg/dL) 22.4  1.7 (212.6  150.6) 2.3  2.0 (203.7  177.1)
Glycosylated hemoglobin value, % 8.0  1.2 7.5  1.1
Urinalysis
Creatinine level, mmol/L (mg/dL) 7.4  2.7 (0.08  0.03) 7.5  2.9 (0.08  0.03)
Albumin excretion rate, g/min 78.6  51.3 89.4  57.0
Creatinine clearance, mL/s
As measured 1.77  0.49 1.68  0.58
Calculated with Cockcroft–Gault formula 1.71  0.60 1.64  0.57
* Values given with a plus/minus sign are the mean  SD. HDL  high-density lipoprotein; LDL  low-density lipoprotein.
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the 236 patients, 147 were randomly assigned. The main
reason for exclusion before randomization was a screening-
phase albumin excretion rate less than 20 g/min, despite
levels between 20 and 200 g/min before enrollment. Of
the 147 patients (full-analysis study sample), 74 were allo-
cated to losartan and 73 were allocated to placebo.
In the losartan group, 3 patients discontinued treat-
ment before the end of the study: 1 just after week 0
because the baseline urinary albumin excretion rate was
retrospectively discovered to be greater than 200 g/min, 1
after week 5 because of a cerebrovascular event within the
preceding year, and 1 just after week 5 because of dizziness
and headache after ingestion of 100 mg of losartan. In the
placebo group, 2 patients discontinued treatment: 1 pa-
tient at week 5 because of a protocol violation (medication
of wrong allocation number was given) and 1 at week 10
because the baseline urinary albumin excretion rate was
retrospectively discovered to exceed 200 g/min.
The remaining 142 patients (71 in each group) com-
pleted the entire study. Baseline characteristics did not sig-
nificantly differ between groups (Table 1).
Albumin Excretion Rate
After 5 weeks of treatment with losartan, 50 mg, the
mean albumin excretion rate was reduced from 78.6 g/
min at baseline to 59.3 g/min (relative reduction, 24.6%)
(Table 2). In the placebo group, the albumin excretion rate
decreased from 89.4 g/min to 83.3 g/min (relative re-
duction, 6.8%). The adjusted mean difference in albumin
excretion rate between the losartan and placebo groups was
16.9 g/min (95% CI, 26.7 to 7.0 g/min; P 
0.001).
At week 5, patients in the losartan group had a fixed-
dose titration to 100 mg of losartan, and patients in the
placebo group continued to receive placebo. After 5 weeks
of treatment with this dose, the mean albumin excretion
rate in the losartan group decreased further, from 78.6
g/min at baseline to 51.9 g/min at week 10 (relative
reduction, 34%). In the placebo group, the mean albumin
excretion rate at week 10 was 97.3 g/min (increase,
10.3%). The difference in the adjusted mean albumin ex-
cretion rate between the losartan and placebo groups
(39.1 g/min [CI, 48.9 to 29.2 g/min]) was sta-
tistically significant (P  0.001). After 10 weeks of treat-
ment with losartan, 8 patients returned to normoalbumin-
uria (albumin excretion rate 20 g/min). In the placebo
group, the minimum urinary albumin excretion rate after
10 weeks was 21 g/min.
The adjusted mean albumin excretion rate decreased
by 8.3 g/min (CI, 0.04 to 16.5 g/min; P  0.049)
when the losartan dose was increased from 50 mg to 100
mg. The antiproteinuric effect of losartan was reversible
after discontinuation of treatment (Table 2, Figure).
Secondary End Points
Losartan was associated with a 9.7% relative reduction
in measured creatinine clearance after 10 weeks of treat-
ment, whereas this measure remained unchanged in the
placebo group (adjusted difference between losartan and
placebo groups, 0.16 mL/s [CI, 0.29 to 0.03 mL/s];
P  0.014). When calculated with the Cockcroft–Gault
formula, creatinine clearance decreased 3.3% in the losar-
tan group and increased 2.7% in the placebo group; this
difference was not statistically significant.
Blood pressure at baseline did not significantly differ
between the losartan and placebo groups. After 5 weeks of
treatment with losartan, 50 mg, mean blood pressure was
reduced from 135.9/78.8 mm Hg to 132.4/76.8 mm Hg;
in the placebo group, blood pressure decreased from
138.3/80.3 mm Hg to 136.1/79.7 mm Hg. The difference
in mean blood pressure reduction between the losartan and
placebo groups was not statistically significant. After 5
weeks of losartan, 100 mg, mean blood pressure decreased
to 131.3/75.8 mm Hg. After 10 weeks of placebo use,
mean blood pressure was 138.4/79.8 mm Hg (adjusted
difference in mean systolic blood pressure between the lo-
Table 2. Effects of Losartan and Placebo on Urinary Albumin Excretion Rate, Creatinine Clearance, and Blood Pressure*
End Point Week 0
(Baseline)
Week 5 (50 mg
of Losartan or
Placebo)






Albumin excretion rate, g/min
Losartan 78.6  51.3 59.3  37.0 51.9  36.8 78.6  64.8
Placebo 89.4  57.0 83.3  57.0 97.3  66.4 102.5  72.8
Creatinine clearance (as measured), mL/s
Losartan 1.77  0.49 1.70  0.64 1.60  0.49 1.72  0.85
Placebo 1.68  0.58 1.67  0.64 1.67  0.60 1.64  0.64
Creatinine clearance (calculated with Cockcroft–Gault formula), mL/s
Losartan 1.71  0.56 1.65  0.59
Placebo 1.64  0.57 1.69  0.63
Systolic blood pressure, mm Hg
Losartan 135.9  10.4 132.4  13.5 131.3  15.6 137.6  10.4
Placebo 138.3  9.7 136.1  12.7 138.4  12.9 141.2  11.3
Diastolic blood pressure, mm Hg
Losartan 78.8  9.4 76.8  9.4 75.8  8.6 78.0  9.1
Placebo 80.3  7.5 79.7  7.9 79.8  7.0 80.7  7.8
* Data are given as the mean  SD.
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sartan and placebo groups, 3.8 mm Hg [CI, 6.5 to
1.1 mm Hg; P  0.006]; difference in diastolic blood
pressure, 2.7 mm Hg [CI, 4.5 to 0.8 mm Hg; P 
0.005]) (Table 2). Blood pressure returned to pretreatment
levels after the 5-week placebo washout period.
Influence of Blood Pressure on Albumin Excretion Rate
At baseline, 62 patients had a blood pressure greater
than 140/90 mm Hg to 150/90 mm Hg, 53 had a pressure
greater than 130/80 to 140/90 mm Hg, and 32 had a
pressure of 130/80 mm Hg or less. The change in mean
albumin excretion rate from baseline to week 10 was inde-
pendent of blood pressure at baseline in both the losartan
and placebo groups (P  0.2 for the interaction between
baseline blood pressure and effect of treatment on albumin
excretion rate in the losartan group and for the interaction
in the placebo group).
Furthermore, in multivariate analysis, the reduction in
albumin excretion rate was independent of the reduction in
blood pressure associated with losartan (P  0.2 for the
interaction between changes in blood pressure and changes
in albumin excretion rate and P  0.001 for the interac-
tion between treatment group and changes in albumin ex-
cretion rate).
Adherence, Tolerability, and Safety
Adherence was high in both treatment groups and at
both doses, ranging from 94.4% in the placebo group to
100% in the 50-mg losartan group.
During the first 5 weeks of treatment, 10 and 12 ad-
verse events, possibly related to the study drug, occurred in
the placebo group and losartan group, respectively. During
the subsequent 5 weeks, the corresponding figures were 3
and 2. All adverse events were mildly or moderately severe.
No patients died.
Laboratory evaluations showed no significant changes
in either treatment group. Neither losartan nor placebo
affected serum potassium, sodium, uric acid, or glycosy-
lated hemoglobin A levels.
DISCUSSION
To our knowledge, this study is the first randomized,
placebo-controlled trial showing that the angiotensin-
receptor antagonist losartan reduces urinary albumin excre-
tion in normotensive patients with type 2 diabetes mellitus
and microalbuminuria. Because 100 mg of losartan re-
duced the albumin excretion rate significantly more than
did the 50-mg dose, our data also show the incremental
benefit of a higher dose. The antiproteinuric effect was
reversible upon discontinuation of losartan therapy. Losar-
tan was well tolerated at both doses.
Treatment with losartan, 50 mg, reduced blood pres-
sure slightly, but the effect was not significantly different
from that in the placebo group. Losartan, 100 mg, resulted
in a somewhat higher but still modest blood pressure re-
duction. However, the reduction in albumin excretion rate
was independent of the decrease in blood pressure associ-
ated with losartan. These findings confirm an independent
renoprotective effect, as postulated in previous studies
(6–8, 21–23). Furthermore, the antiproteinuric effect of
losartan was consistent across different baseline blood pres-
sures, including patients who are normotensive according
to the current definition.
The IRMA (Irbesartan Type II Diabetes with Mi-
croalbuminuria) trial studied the effect of the angiotensin-
receptor antagonist irbesartan on the progression of mi-
croalbuminuria to overt proteinuria in hypertensive
patients with type 2 diabetes (21). In that study, 150 and
300 mg of irbesartan were compared with placebo for the
time to onset of overt nephropathy, changes in albumin-
uria, and creatinine clearance. The albumin excretion rate
decreased by 24% with 150 mg of irbesartan and by 38%
with 300 mg. The steepest decrease in albumin excretion
rate occurred within the first 3 months of treatment. In our
study, 50 mg of losartan resulted in a 25% relative reduc-
tion in the albumin excretion rate, compared with a 34%
reduction with 100 mg. Thus, the antiproteinuric effects of
losartan in our study appear to be qualitatively and quan-
titatively comparable to those of losartan and irbesartan in
previous studies in hypertensive patients with diabetes mel-
litus (14, 16, 18, 19).
As stated, the IRMA trial showed a significant addi-
tional 14–percentage point reduction in microalbuminuria
with a double dose of irbesartan (21), a finding similar to
ours. As shown in previous studies that investigated the
time course of the antiproteinuric response of angiotensin-
receptor antagonists and ACE inhibitors (28–30), the in-
cremental reduction in albumin excretion with losartan,
100 mg, appears attributable to a dose response rather than
a time response. In patients with type 1 diabetes and mi-
croalbuminuria, the antiproteinuric response to losartan
Figure. Time course of the effect of losartan and placebo on
mean urinary albumin excretion rate.
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was maximal within 1 week of treatment, and these
changes paralleled those in blood pressure and renal hemo-
dynamics (28). In nondiabetic patients with proteinuria
and patients with type 1 diabetes mellitus and macropro-
teinuria, the antiproteinuric effects of losartan and enala-
pril were maximal within 4 weeks of treatment. Increasing
the dose further reduced albuminuria; maximal effect was
seen within 4 weeks (29, 30).
In the losartan-treated patients, the measured creati-
nine clearance decreased compared with baseline levels and
compared with the placebo recipients. The difference be-
tween the measured and calculated clearance can be ex-
plained by inaccuracy of urine collection; the Cockcroft–
Gault formula corrects this discrepancy. As known from
other studies of ACE inhibitors and losartan in patients
with early diabetic nephropathy, creatinine clearance stabi-
lizes after prolonged treatment (6, 10, 11, 14, 17, 21–23,
31). The initial decrease is thought to result from renal
hemodynamic factors and is reversible after withdrawal of
medication (10, 17). The extent of the reduction in creat-
inine clearance in our study is similar to that seen in other
studies.
Losartan at both doses was well tolerated, with a safety
profile similar to that of placebo. These findings parallel
observations made by others studying the nephroprotective
effect of losartan in hypertensive diabetic patients (13, 14,
23). Of note, our study shows that normotensive patients
can be treated safely with the antihypertensive drug losartan.
A possible site of action of angiotensin-receptor antag-
onists in normotensive diabetic patients is the vascular en-
dothelium. Endothelial dysfunction has been associated
with increased urinary albumin excretion, as well as with
an increased risk for cardiovascular events in type 2 diabe-
tes (32, 33). Inhibition of urinary albumin excretion may
reflect recovery of endothelial function and may predict a
reduction in the risk for complications.
One of the main limitations of our study is the brief
follow-up period. However, the study was established to
investigate whether losartan reduced microalbuminuria in
normotensive patients with type 2 diabetes, since to our
knowledge it is the first trial reported in this patient pop-
ulation. Furthermore, our study evaluated the effect of lo-
sartan on surrogate outcomes (albumin excretion rate), and
therefore our findings cannot be extrapolated to hard clin-
ical end points; however, microalbuminuria is considered
to be predictive of renal and cardiovascular morbidity
(2–5, 32).
A comparison with an ACE inhibitor or other antihy-
pertensive drug would be of interest. However, when we
developed the protocol, antihypertensive treatment of pa-
tients with type 2 diabetes mellitus and a blood pressure of
150/90 mm Hg or less was not the standard of care, nor
was ACE inhibitor treatment of normotensive patients
with type 2 diabetes and microalbuminuria. Accordingly,
we had no reason to include a comparison group beyond
placebo. Furthermore, investigating whether angiotensin-
receptor antagonists have an advanced antiproteinuric ef-
fect over ACE inhibitors in this population would require
an extremely large study because of the expected similar
effects of both agents.
In conclusion, our data show that the angiotensin-
receptor antagonist losartan reduces urinary albumin excre-
tion in normotensive patients with type 2 diabetes mellitus
and microalbuminuria. The antiproteinuric effects of ACE
inhibitors and angiotensin antagonists in hypertensive dia-
betic patients decrease the risk for overt nephropathy, end-
stage renal disease, and cardiovascular events (9, 11, 14,
21–24). Therefore, a long-term, large-scale clinical trial,
preferably comparing losartan with an ACE inhibitor and
other antihypertensive agents, is required to investigate the
effects of losartan on hard clinical end points in normoten-
sive patients with type 2 diabetes, with treatment started at
a stage as early as microalbuminuria.
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APPENDIX
The following centers and investigators in the Netherlands
participated in the study: Ikazia Hospital (A.A.M. Zandbergen,
M.G.A. Baggen, R.J.Th. Ouwendijk); Sint Franciscus Hospital
(J.W.F. Elte); Vlietland Hospital, Vlaardingen (S.G.T. Hulst);
Rotterdam Eye Hospital (Th.L.J.M. van der Loos); Erasmus
University Medical Centre (S.W.J. Lamberts, A.H. Bootsma);
University Hospital Maastricht (T.W.A. de Bruin); Albert
Schweitzer Hospital, Zwijndrecht (R.J.M. van Leendert); Diabe-
tes Centre Bilthoven (G.E.M.G. Storms); Isala Clinics, location
Sophia (J. Lambert); Atrium Medical Centre, Brunssum
(W.J.J.R. Venekamp); Medical Centre Alkmaar (W. Bronsveld);
Gelre Hospitals, location Lukas (R.P. Verhoeven); University
Medical Centre St Radboud (L.D. Elving); Hospital Walcheren
(W.L. Blok); Albert Schweitzer Hospital, location Dordwijk
(B.M. van Ouwerkerk); Ruwaard van Putten Hospital (M.H.
Silbermann); Ma´xima Medical Centre, location Veldhoven (R.J.
Erdtsieck); Hofpoort Hospital (J.W. van der Beek-Boter); Rode
Kruis Hospital (G. Schrijver).
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